Cancer drugs under watch: Real-World safety check begins
NCT ID NCT06995833
Summary
This study aims to monitor the safety and real-world effectiveness of two approved cancer drugs, durvalumab and olaparib, in patients with endometrial cancer in Korea. It will follow about 50 patients for up to a year after they start treatment as part of their normal medical care. The goal is to gather information on how well the drugs work and what side effects occur outside of a controlled clinical trial setting.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGSeoul, South Korea
Conditions
Explore the condition pages connected to this study.